April 12, 2017
Apr 12, 2017
In November of 2014, SV Life Sciences, a Boston-based private equity firm, acquired a majority stake in Ximedica, enabling the company to execute its growth strategy.
SV Life Sciences recently featured Ximedica CEO Randy Barko and the company on their website.
“Although there are many companies doing outsourced device R&D, most are small – groups of good engineers who’ve set up shop and built $1 – 2 million in revenue,” says SV managing partner Paul LaViolette. “But Ximedica was different. It had a 20-year history. The company had reached significant revenue, achieved profitability and overcome myriad barriers that prevent most companies from achieving such scale…we helped the Ximedica team think bigger and we enabled them to shine. This management team has immense capacity.”
To read the full feature, visit the SV Life Sciences website here.